Testosterone Lawsuit Alleges Fortesta Caused Georgia Man to Suffer Heart Attack, Bernstein Liebhard LLP Reports

Share Article

The Firm is evaluating testosterone treatment lawsuits on behalf of men who allegedly suffered serious cardiovascular injuries due to the use of Fortesta and other low testosterone therapies.

Free Case Review
Our Firm has heard from numerous men who used drugs like Fortesta and allegedly suffered serious heart injuries similar to those cited in this complaint.

A new testosterone lawsuit (http://www.testosteronelawsuitcenter.com/)
has been filed by a Georgia heart attack victim in Pennsylvania against the manufacturer of Fortesta, Bernstein Liebhard LLP reports. The complaint, which was filed on May 8th in the Philadelphia Court of Common Pleas, alleges that Endo Pharmaceuticals Inc. and Prostrakan Group PLC, failed to provide adequate warnings regarding the increased risk of heart attacks and other cardiovascular injuries associated with the use of the low testosterone therapy. The complaint also questions the marketing tactics used to drive sales of Fortesta, alleging that the companies encouraged men to seek treatment for listlessness, low libido, moodiness and other symptoms which were merely the result of aging or lifestyle choices, rather than low testosterone. (Taylor et al v. Endo Pharmaceuticals Inc., case number 140500775).

“Our Firm has heard from numerous men who used drugs like Fortesta and allegedly suffered serious heart injuries similar to those cited in this complaint,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free testosterone lawsuit reviews to anyone who may have suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism, or other serious heart problems allegedly due to the use of prescription testosterone therapies.

Testosterone Lawsuits
According to court documents, the litigation involving Fortesta and other low testosterone medications has been growing since late January, when the Food & Drug Administration (FDA) announced it was investigating the heart risks potentially associated with low testosterone therapies. The FDA’s review was launched in response to a growing body of research that suggests these medications might raise the risk of heart attacks, strokes, and death in certain men.

Court filings indicate that the U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear oral arguments on May 29th regarding a proposal to consolidate all federally-filed testosterone lawsuits involving the drug AndroGel in a single federal court for coordinated pretrial proceedings. The manufacturers of AndroGel, Axiron and Fortesta have voiced support for the establishment of a multidistrict litigation, but have requested that the proceeding include all federal testosterone claims, regardless of the drugs involved. (In Re: AndroGel Product Liability Litigation, No. 2545, JPML)

Victims of heart attacks, strokes, or other heart problems allegedly caused by low testosterone therapies may be eligible to file their own testosterone lawsuit. To learn more about this growing litigation, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website